AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15699689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide formula (1.5 g/L)
Number of subjects: 72
Study 15699689 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide formula (3.0 g/L)
Number of subjects: 72
Study 15699689 — intervention group
Group type: COMPARATOR
Intervention: Control (human milk)
Number of subjects: 72
Study 15699689 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented formula)
Number of subjects: 72
Study 11914742 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in polyunsaturated fatty acids
Number of subjects: 17
Study 11914742 — intervention group
Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids
Number of subjects: 17
Study 10446816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg every 6 hrs for a total of four doses
Number of subjects: 40
Study 10446816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg as a single dose
Number of subjects: 40
Study 10446816 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study 7844602 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) genetically modified with a retroviral vector containing the NeoR gene.
Number of subjects: 5
Study 2085872 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate therapy (2 x 20 mg IS‐5‐MN and 1 x 120 mg ISDN sustained release)
Number of subjects: 10
Study 2085872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 454092 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 454092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 0
Study 454092 — intervention group
Group type: COMPARATOR
Intervention: MAO inhibitors
Number of subjects: 0
Study 454092 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0
Study 7082211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 0
Study 7082211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30016404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision Harmonic Scalpel
Number of subjects: 57
Study 30016404 — intervention group
Group type: EXPERIMENTAL
Intervention: PEAK-Plasmablade
Number of subjects: 57
Study 30016404 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 57
Study 30016404 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC)
Number of subjects: 57
Study 30016404 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods evaluated
Number of subjects: 57
Study 30061523 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 (full DMLS)
Number of subjects: 50
Study 30061523 — intervention group
Group type: COMPARATOR
Intervention: T2 (machined upper and DMLS lower)
Number of subjects: 50
Study 30061523 — intervention group
Group type: COMPARATOR
Intervention: T3 (DMLS upper and machined lower)
Number of subjects: 50
Study 30061523 — intervention group
Group type: COMPARATOR
Intervention: T4 (full machined)
Number of subjects: 50
Study 27568389 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pressure input during wisdom tooth extraction
Number of subjects: 0
Study 27568389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no deep pressure input)
Number of subjects: 0
Study 24967760 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol-driven teaching program
Number of subjects: 18
Study 24967760 — intervention group
Group type: COMPARATOR
Intervention: Non-protocol driven teaching program
Number of subjects: 18
Study 22525398 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribosome-component immune modulator (RCIM)
Number of subjects: 164
Study 22525398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 20494239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (improvement in diet, increase in physical activity, reduction in cigarette smoking through educational interviews, lectures, and publications)
Number of subjects: 1754
Study 20494239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 1754
Study 20494239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 1754
Study 20494239 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1754
Study 18043056 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh blade
Number of subjects: 11
Study 18043056 — intervention group
Group type: COMPARATOR
Intervention: Miller blade
Number of subjects: 11
Study 16096858 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) 250 mg twice a week for 12 weeks
Number of subjects: 18
Study 16096858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12399139 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 12399139 — intervention group
Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 0
Study 12399139 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 9951979 — intervention group
Group type: EXPERIMENTAL
Intervention: SB MMR vaccine (Priorix; SmithKline Beecham Biologicals)
Number of subjects: 4702
Study 9951979 — intervention group
Group type: COMPARATOR
Intervention: Merck MMR vaccine (M‐M‐R II; Merck & Co. Inc)
Number of subjects: 4702
Study 7495925 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol pretreatment
Number of subjects: 11
Study 7495925 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212
Number of subjects: 11
Study 2178931 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 66
Study 2178931 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin in association with cholestyramine
Number of subjects: 66
Study 2178931 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 66
Study 35208 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg three times daily
Number of subjects: 0
Study 35208 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (investigational 1,5-benzodiazepine)
Number of subjects: 0
Study 35208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29317191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg every 2 weeks with erlotinib 150 mg/d
Number of subjects: 14
Study 29317191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 28557758 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat antenatal betamethasone
Number of subjects: 185
Study 28557758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single course)
Number of subjects: 185
Study 25679172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose calculation during optimization
Number of subjects: 11
Study 22975755 — intervention group
Group type: COMPARATOR
Intervention: Golimumab treatment
Number of subjects: 100
Study 22216750 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole
Number of subjects: 0
Study 22216750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18212177 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) treatment
Number of subjects: 43
Study 16357874 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 0
Study 16357874 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 0
Study 14597940 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacemaker programmed to dual-chamber pacing
Number of subjects: 2010
Study 14597940 — intervention group
Group type: COMPARATOR
Intervention: Dual-chamber pacemaker programmed to ventricular pacing
Number of subjects: 2010
Study 10871094 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% balsam of Peru in petrolatum applied for 3, 6, 24, 48, 72, and 96 hours
Number of subjects: 13
Study 10871094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent foils with petrolatum test substance
Number of subjects: 13
Study 10871094 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial doses printed on polyester squares
Number of subjects: 13
Study 9339881 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg once daily
Number of subjects: 278
Study 9339881 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine IR 37.5 mg twice daily
Number of subjects: 278
Study 9339881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 9339881 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 278
Study 8366227 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPe 35% of intrinsic PEEP (PEEPi)
Number of subjects: 9
Study 8366227 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPe 58% of intrinsic PEEP (PEEPi)
Number of subjects: 9
Study 8366227 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPe 86% of intrinsic PEEP (PEEPi)
Number of subjects: 9
Study 8366227 — intervention group
Group type: COMPARATOR
Intervention: Control (no PEEPe)
Number of subjects: 9
Study 3518765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.6 mg kg‐1 (Group I, 20 patients)
Number of subjects: 30
Study 3518765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg kg‐1 (Group II, 10 patients)
Number of subjects: 30
Study 3518765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (both groups)
Number of subjects: 30
Study 29970072 — intervention group
Group type: EXPERIMENTAL
Intervention: Arctostaphylos uva‐ursi (UU, bearberry extract arbutin) 105 mg, 3 times a day for 5 days
Number of subjects: 0
Study 29970072 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin 3 g once
Number of subjects: 0
Study 26474809 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP) plus usual care
Number of subjects: 1645
Study 26474809 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurse Partnership (FNP)
Number of subjects: 1645
Study 26474809 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1645
Study 25917376 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly structured pharmaceutical care visits delivered by pharmacists for 6 months
Number of subjects: 68
Study 25917376 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetic care
Number of subjects: 68
Study 24322383 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir
Number of subjects: 689
Study 24322383 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir
Number of subjects: 689
Study 20107144 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment at 0 and 3 months
Number of subjects: 591
Study 20107144 — intervention group
Group type: COMPARATOR
Intervention: Iron-fortified biscuits providing an additional 20 mg iron/d as electrolytic iron 4 times/week
Number of subjects: 591
Study 20107144 — intervention group
Group type: COMPARATOR
Intervention: IPT of malaria with sulfadoxine-pyrimethamine at 0 and 3 months
Number of subjects: 591
Study 19175162 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-factor guided LASIK
Number of subjects: 84
Study 19175162 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK
Number of subjects: 84
Study 15990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing method with capsaicin 0.4 micromol/L
Number of subjects: 30
Study 15990345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosimeter method with capsaicin 0.4 micromol/L
Number of subjects: 30
Study 15990345 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 12946758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 580
Study 12946758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 580
Study 12946758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 580
Study 12946758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study 11041173 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with preservation of subvalvular structure (MVRP)
Number of subjects: 68
Study 8856838 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 1.0 mg
Number of subjects: 15
Study 8856838 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.3 mg
Number of subjects: 15
Study 8856838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1290313 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 100
Study 1290313 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pravastatin)
Number of subjects: 100
Study 6235249 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg b.i.d.
Number of subjects: 11
Study 6235249 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 600 mg b.i.d.
Number of subjects: 11
Study 6235249 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 600 mg q.i.d.
Number of subjects: 11
Study 6235249 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg in the morning, 50 mg at noon, and 100 mg h.s.
Number of subjects: 11
Study 6235249 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 375 mg b.i.d.
Number of subjects: 11
Study 31489589 — intervention group
Group type: EXPERIMENTAL
Intervention: Apalutamide with ongoing ADT
Number of subjects: 0
Study 31489589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29514163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 2 mg/day for days 1-28 with regorafenib
Number of subjects: 0
Study 26820395 — intervention group
Group type: EXPERIMENTAL
Intervention: Heracleum persicum hydroalcoholic fruit extract (300 mg/day)
Number of subjects: 27
Study 26820395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 25634390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin and lignocaine (3 ml solution) infiltrated subcutaneously at the site intended for puncture (Group NL)
Number of subjects: 200
Study 25634390 — intervention group
Group type: COMPARATOR
Intervention: Saline and lignocaine infiltrated subcutaneously (Group SL)
Number of subjects: 200
Study 22939439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 481
Study 22939439 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 481
Study 20145564 — intervention group
Group type: COMPARATOR
Intervention: Nonstretching (NS)
Number of subjects: 15
Study 20145564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume PNF stretching (LVPNFS)
Number of subjects: 15
Study 20145564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume PNF stretching (HVPNFS)
Number of subjects: 15
Study 20145564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume static stretching (LVSS)
Number of subjects: 15
Study 20145564 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume static stretching (HVSS)
Number of subjects: 15
Study 18042603 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Number of subjects: 32
Study 18042603 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 32
Study 16061897 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluator perspective
Number of subjects: 1253
Study 16061897 — intervention group
Group type: COMPARATOR
Intervention: Social decision-maker perspective
Number of subjects: 1253
Study 11838888 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, low-fat diet
Number of subjects: 10
Study 11838888 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, low-fat diet
Number of subjects: 10
Study 10422354 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding therapy
Number of subjects: 0
Study 10422354 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7768080 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (2.5 to 20 mg) once daily
Number of subjects: 239
Study 7768080 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (oral)
Number of subjects: 239
Study 1416266 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray, 100 micrograms per nostril twice a day
Number of subjects: 50
Study 1416266 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 50
Study 3998201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (single dose)
Number of subjects: 4
Study 3998201 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg (multiple doses, 200 mg every six hours and 400 mg before retiring)
Number of subjects: 4
Study 3998201 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 750 mg (single dose alone)
Number of subjects: 4
Study 30786924 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-associated antibodies (NY-ESO-1)
Number of subjects: 0
Study 30786924 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-associated antibodies (MelanA/MART1)
Number of subjects: 0
Study 30786924 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-associated antibodies (gp100)
Number of subjects: 0
Study 30786924 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-associated antibodies (TRP1/TYRP1)
Number of subjects: 0
Study 30786924 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-associated antibodies (TRP2/TYRP2)
Number of subjects: 0
Study 29730186 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume (HV, 350 mL) water load
Number of subjects: 19
Study 29730186 — intervention group
Group type: COMPARATOR
Intervention: Low volume (LV, 50 mL) water load
Number of subjects: 19
Study 26738952 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered Diesel Exhaust (DE)
Number of subjects: 26
Study 26738952 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered Diesel Exhaust (DE)
Number of subjects: 26
Study 26738952 — intervention group
Group type: COMPARATOR
Intervention: Clean Air
Number of subjects: 26
Study 24452238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavonoid (HF) fruit and vegetables
Number of subjects: 174
Study 24452238 — intervention group
Group type: COMPARATOR
Intervention: Increase in fruit and vegetables (regardless of flavonoid content)
Number of subjects: 174
Study 22704052 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of easily visible seroma
Number of subjects: 648
Study 22704052 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of breast seroma
Number of subjects: 648
Study 20304499 — intervention group
Group type: EXPERIMENTAL
Intervention: CF101 (1 mg, orally, twice daily for 12 weeks)
Number of subjects: 68
Study 20304499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching vehicle-filled pills, orally, twice daily for 12 weeks)
Number of subjects: 68
Study 19030213 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS formula (0.24 g/100 mL)
Number of subjects: 371
Study 19030213 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 371
Study 19030213 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula without GOS
Number of subjects: 371
Study 19030213 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS formula
Number of subjects: 371
Study 15845693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 40
Study 11922254 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 12
Study 11922254 — intervention group
Group type: COMPARATOR
Intervention: Autogenous free gingival graft (FGG)
Number of subjects: 12
Study 9611938 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 10
Study 9611938 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 7837002 — intervention group
Group type: EXPERIMENTAL
Intervention: Displays without noise points
Number of subjects: 0
Study 7837002 — intervention group
Group type: COMPARATOR
Intervention: Displays with noise points
Number of subjects: 0
Study 2964344 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 2 percent gel
Number of subjects: 187
Study 2964344 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 187
Study 29203184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified transurethral enucleation and resection of the prostate (M‐TUERP)
Number of subjects: 86
Study 29203184 — intervention group
Group type: COMPARATOR
Intervention: Conventional bipolar transurethral resection of the prostate (B‐TURP)
Number of subjects: 86
Study 26433607 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS to the contralateral motor cortex
Number of subjects: 20
Study 26433607 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 20
Study 25707524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 37
Study 25707524 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 37
Study 25707524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and Remifentanil
Number of subjects: 37
Study 22407663 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation for 12 min per day for 8 weeks
Number of subjects: 39
Study 22407663 — intervention group
Group type: COMPARATOR
Intervention: Listening to relaxation music for 12 min per day for 8 weeks
Number of subjects: 39
Study 19923383 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nonheme iron intake at baseline
Number of subjects: 2895
Study 19923383 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd tertile of nonheme iron intake at baseline
Number of subjects: 2895
Study 19923383 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron intake
Number of subjects: 2895
Study 19923383 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 2895
Study 19923383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin and ferritin concentrations
Number of subjects: 2895
Study 18227236 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsidized coverage at $20 per month
Number of subjects: 0